Kerendia Could Be Next Jewel In Bayer's Pharma Crown

 
• By Kevin Grogan

CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

Bayer q2 24
Bill Anderson (r) with chief financial officer Wolfgang Nickl • Source: Bayer

More from Earnings

More from Business